Mathias Rummel - Concepedia

Author

Mathias Rummel

Also Known As

C. Nerl, M Rummel, M. J . Rummel, M. J. Rummel, M. Rummel, M.J Rummel, M.J. Rummel, Maloney, D, Mathias J Rummel, Mathias J. Rummel

209

Publications

Citations

H-Index

Concepts

All Affiliations

Justus-Liebig-Universität Gießen Goethe University Frankfurt Universitätsklinikum Gießen und Marburg Medizinische Hochschule Hannover University Hospital Frankfurt

About

Mathias Rummel is an author at Justus-Liebig-Universität Gießen specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	24	36	3.6K
2	Health Sciences	13	14	1.9K
3	Cell Biology	4	4	73
4	Engineering	1	1	11
5	Biomolecular Engineering	1	1	73

Mathias Rummel

Publications

7.7K

Citations

H-Index

Page 1

	Year	Citations
Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial Mathias Rummel, N. Niederle, Georg Maschmeyer, The Lancet Lymphoid NeoplasiaRituximab Versus ChopOncologyMantle-cell LymphomasMetronomic Therapy	2013	1.5K
Escalated-Dose BEACOPP in the Treatment of Patients With Advanced-Stage Hodgkin's Lymphoma: 10 Years of Follow-Up of the GHSG HD9 Study Andreas Engert, Volker Diehl, Jeremy Franklin, Journal of Clinical Oncology	2009	494
The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML Sabine Käyser, Konstanze Döhner, Jürgen Krauter, Blood	2010	479
Bendamustine Plus Rituximab Is Effective and Has a Favorable Toxicity Profile in the Treatment of Mantle Cell and Low-Grade Non-Hodgkin's Lymphoma Mathias Rummel, S. Al-Batran, Soo-Z. Kim, Journal of Clinical Oncology	2005	439
Romiplostim or Standard of Care in Patients with Immune Thrombocytopenia David J. Kuter, Mathias Rummel, Ralph V. Boccia, New England Journal of Medicine	2010	417
Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial Andrés J.M. Ferreri, Kate Cwynarski, Elisa Jacobsen Pulczynski, The Lancet Haematology Neuro-oncologyRadiation OncologyLymphoid NeoplasiaTransplantationCell Therapy	2017	364
Long‐term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy David J. Kuter, James B. Bussel, Adrian C. Newland, British Journal of Haematology	2013	270
RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features Verena I. Gaidzik, Veronica Teleanu, Elli Papaemmanuil, Leukemia Hematological MalignancyMedicineGeneticsAcute Myeloid LeukemiaHematology	2016	264
Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia Robert J. Kreitman, Claire Dearden, Pier Luigi Zinzani, Leukemia	2018	233
Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases. Kai Uwe Chow, Wolf Daniel Sommerlad, Simone Boehrer, PubMed	2002	186

Page 1